Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
CPO301
i
Other names:
CPO301, SYS6010, CPO 301, CPO-301, SYS 6010, SYS-6010
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
CSPC Pharma
Drug class:
EGFR-targeted antibody-drug conjugate
Related drugs:
‹
HTI-1511 (7)
DM001 (6)
MRG003 (6)
ABBV-321 (6)
LR004-VC-MMAE (5)
SHR-A1307 (4)
M1231 (3)
ABT-414 (3)
BB-1705 (2)
DM005 (2)
ABBV-221 (2)
AZD9592 (2)
BL-B01D1 (1)
ABBV-637 (0)
AVID100 (0)
IMGN289 (0)
HTI-1511 (7)
DM001 (6)
MRG003 (6)
ABBV-321 (6)
LR004-VC-MMAE (5)
SHR-A1307 (4)
M1231 (3)
ABT-414 (3)
BB-1705 (2)
DM005 (2)
ABBV-221 (2)
AZD9592 (2)
BL-B01D1 (1)
ABBV-637 (0)
AVID100 (0)
IMGN289 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1, N=102, Recruiting, Conjupro Biotherapeutics, Inc.
over 1 year ago
New P1 trial • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
EGFR mutation • KRAS wild-type • RAS wild-type
|
CPO301
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login